Home>Topics>Stocks>Affymax

Affymax AFFY

  1. All
  2. Commentary
  3. Stock Reports
  4. ETF Reports
  5. Headlines
    1. New Morningstar Analyst Report for Amgen Inc

      Stock Reports

      Tue, 18 Mar 2014

      per share from $101, as we have slightly increased our assumptions for Aranesp and Epogen sales following the withdrawal of Affymax 's Omontys from the market. Amgen's global ESA sales saw high-single-digit declines in 2012, and we expect this high

    2. Is Affymetrix 'Sequencing' A Turnaround, Or Just A Devolving Genetic Anomaly?

      Headlines

      Mon, 12 Aug 2013

      By Tim Gallagher : A trailblazing pioneer, Affymetrix ( AFFY ) got off largely under-the-radar in 1992, and came public with its IPO in June 1996. AFFX "blasted-off" like a rocket

    3. Affymax may consider filing for bankruptcy; cuts workforce by 75 percent

      Headlines

      Mon, 18 Mar 2013

      (Reuters) - Drug maker Affymax Inc said it may consider selling itself or filing for bankruptcy among a range of strategic alternatives as it struggles with the recent recall of its sole commercial product, the anemia drug Omontys.

    4. Affymax may consider filing for bankruptcy; cuts workforce by 75 pct

      Headlines

      Mon, 18 Mar 2013

      March 18 (Reuters) - Affymax Inc, which recalled its anemia drug Omontys in February, said it may consider selling itself or filing for bankruptcy among a range of strategic alternatives.

    5. Affymax stock plunges 85 percent on drug recall

      Headlines

      Mon, 25 Feb 2013

      (Reuters) - Shares of Affymax Inc fell 85 percent after it said serious adverse reactions, including death, were reported among some of those using its sole commercial product, anemia drug Omontys.

    6. Amgen's Enbrel Sees Outstanding 2012, but Neulasta Worries Keep Our Long-Term Forecast Conservative

      Commentary

      Thu, 24 Jan 2013

      Aranesp pressure was expected, and Epogen declines appear to be caused more by competition (albeit minimal) from Affymax 's AFFY Omontys and less from the decreased ESA usage due to bundled reimbursement that has plagued growth in previous quarters

    7. No Surprises in Amgen's First Quarter; Raising Our Fair Value Estimate on Pipeline Progress

      Commentary

      Tue, 24 Apr 2012

      operators DaVita DVA and Fresenius FMS, we think future biosimilar competition--as well as branded products like Affymax 's AFFY recently approved anemia drug Omontys--cloud Epogen's long-term prospects. We're forecasting continued double-digit

    8. Amgen's Micromet Acquisition and Strong 2012 Outlook Are Positives, but Shares Look Fairly Valued

      Commentary

      Thu, 26 Jan 2012

      sign for near-term sales. However, the DaVita deal only covers one third of the U.S. dialysis market, and Affymax 's AFFY Hematide--a more convenient and potentially cheaper option in a price-sensitive market--could receive Food

    9. Dropping Coverage of Affymax

      Commentary

      Mon, 11 Oct 2010

      We are dropping coverage of Affymax AFFY to focus our resources elsewhere.

    « Prev123Next »
    Content Partners